Meropenem Kabi (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to loss of cell‑wall integrity, bacterial lysis, and death, providing broad‑spectrum activity against many resistant Gram‑negative, Gram‑positive, and anaerobic organisms.

The dose of Meropenem Kabi is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. No fixed regimen is provided here; the prescriber tailors therapy to each individual case.

Limited clinical data exist for Meropenem use in pregnancy and lactation. It should be prescribed only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under the guidance of a qualified healthcare professional.

To place an order, submit an enquiry on the Meropenem Kabi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Meropenem offers a broader spectrum against Pseudomonas aeruginosa and many β‑lactamase‑producing organisms compared with imipenem‑cilastatin, and it has a lower risk of seizures than ertapenem at standard doses. Choice of carbapenem depends on local resistance patterns, infection site, and patient‑specific factors.

Meropenem Kabi should be stored refrigerated between 2 °C and 8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial before reconstitution.

The sterile powder is reconstituted with the appropriate diluent and administered intravenously, typically as a 15‑ to 30‑minute infusion. Administration details, including infusion rate and compatible solutions, are provided in the prescribing information and should be followed by qualified healthcare personnel.

Serious adverse events include seizures, especially in patients with renal impairment or high doses; severe hypersensitivity reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis, which can be life‑threatening. Prompt medical attention is required if any of these occur.

Meropenem Kabi is contraindicated in individuals with a documented hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures or severe renal impairment, and dosing adjustments are required in such cases.